How should CARs and bispecifics be selected and sequenced in LBCL?

In this video, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, provides an overview of the CAR T-cell products and bispecific T-cell engagers approved for the treatment of patients with large B-cell lymphoma (LBCL) in the second and third-line settings and discusses how these therapeutic options should be selected and sequenced based on available data. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.